奧瑞許科技 OSUR 深 滬
已收盤 02-06 16:00:00 美东时间
2.71
-0.020
-0.73%
華盛通- 最 高2.81
- 今 開2.77
- 成交量 45.34万股
- 最 低 2.70
- 昨 收 2.73
- 總市值 1.94亿
- 52周最高 4.22
- 市盈率 靜 --
- 換手率 0.63%
- 52周最低 2.08
- 委 比 -55.53%
- 總股本 7173.35万
- 歷史最高 23.01
- 量 比 0.75
- 振 幅 4.03%
- 歷史最低 2.08
- 每 手 1
- 風險率 0.40%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Altai Capital nominates two directors to OraSure's board
Altai Capital nominated two candidates for election to OraSure's (OSUR) board. Orasure rose 1.7%. Altai Capital, which has a 5.2% stake in OraSure (OSUR), nominated Digital Diagnostics CEO John Bertra...
01-15 23:32
OraSure Technologies Confirms Receipt of Director Nominations from Altai Capital
OraSure Technologies announced that Altai Capital has nominated two candidates, including Rishi Bajaj, for its 2026 Board of Directors election. The Board has engaged with Altai but ultimately declined to accept their nominations, maintaining its independence. OraSure has refreshed its Board since 2022, adding three new independent directors, including Steven K. Boyd, and appointing John P. Kenny as Chair. The Board will review Altai's nomination...
01-15 18:00
OraSure Submits Two Separate Applications At 2025 End To FDA For Clearance Of Rapid Molecular Self-Test For CT/NG As Well As Colli-Pee At-Home Urine Collection Device For STIs
OraSure Technologies, Inc. (NASDAQ:OSUR) ("OraSure" and "OTI"), a leader in point-of-need and home diagnostic tests and sample management solutions, today announced that it submitted two separate applications at the end
01-05 21:04
OraSure Submits CT/NG Molecular Self-Test and Colli-Pee™ Urine Collection Device for FDA Review
OraSure Technologies, Inc. has submitted two applications to the FDA for clearance of its rapid molecular self-test for Chlamydia trachomatis and Neisseria gonorrhoeae (CT/NG) and its Colli-Pee™ at-home urine collection device for sexually transmitted infections. These submissions reflect progress toward decentralizing diagnostics and improving accessibility, convenience, and privacy of testing. The CT/NG self-test, built on the Sherlock platform...
01-05 13:00
Altai Capital plans to nominate two directors to OraSure's board
Altai Capital Management said it plans to nominate two candidates for election to OraSure's (OSUR) board. Altai Capital, which has a 5.2% stake in OraSure (OSUR), will nominate Digital Diagnostics CEO...
2025-12-17 21:44
OraSure Technologies Executives Adopt Stock Trading Plans
Orasure Technologies ( ($OSUR) ) has issued an update. On December 1, 2025, Ora...
2025-12-01 20:58
OraSure to Participate in Upcoming Investor Conference
OraSure Technologies, Inc. will participate in the Stephens Annual Investment Conference on November 19, 2025, with a Q&A session at 10 a.m. CT. A live webcast and replay will be available on OraSure’s investor relations page. The company transforms health through innovative diagnostics and decentralizes healthcare solutions, offering rapid diagnostic tests and sample management devices globally.
2025-11-17 12:45
美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
2025-11-13 09:58
Stephens & Co. Maintains Equal-Weight on OraSure Technologies, Lowers Price Target to $3
Stephens & Co. analyst Steven Etoch maintains OraSure Technologies (NASDAQ:OSUR) with a Equal-Weight and lowers the price target from $3.5 to $3.
2025-11-12 22:07
OraSure Technologies Q3 Adj. EPS $(0.13) Beats $(0.20) Estimate, Sales $27.085M Miss $28.960M Estimate
OraSure Technologies (NASDAQ:OSUR) reported quarterly losses of $(0.13) per share which beat the analyst consensus estimate of $(0.20) by 35 percent. This is a 1200 percent decrease over losses of $(0.01) per share from
2025-11-06 05:28
